Treatment of intravaginal HSV-2 infection in mice: A comparison of CpG oligodeoxynucleotides and resiquimod (R-848)

Antiviral Research

Volumn 69, Issue 2, 2006, Pages 77-85

  McCluskie, Michael J ^a   Cartier, Janna L M ^a   Patrick, Amy J ^b   Sajic, Dusan ^b   Weeratna, Risini D ^a   Rosenthal, Kenneth L ^b   Davis, Heather L ^a  

^a Coley Pharmaceutical Group ^*  (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

CpG ODN; HSV 2; Innate; R 848; TLR; Vaginal

Indexed keywords

CHEMOKINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; RESIQUIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VAGINA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CPG ISLANDS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; TREATMENT OUTCOME; VAGINA;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 2; MAMMALIA;

EID: 31444448763     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.10.007     Document Type: Article

References (49)

1. A.A. Ashkar, S. Bauer, W.J. Mitchell, J. Vieira, and K.L. Rosenthal Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2 J. Virol. 77 2003 8948 8956
2. M. Bauer, V. Redecke, J.W. Ellwart, B. Scherer, J.P. Kremer, H. Wagner, and G.B. Lipford Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells J. Immunol. 166 2001 5000 5007
3. S. Bauer, C.J. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. Wagner, and G.B. Lipford Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition Proc. Natl. Acad. Sci. U.S.A. 98 2001 9237 9242
4. D.I. Bernstein, and C.J. Harrison Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections Antimicrob. Agents Chemother. 33 1989 1511 1515
5. D.I. Bernstein, C.J. Harrison, M.A. Tomai, and R.L. Miller Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment J. Infect. Dis. 183 2001 844 849
6. A.M. Cole, T. Ganz, A.M. Liese, M.D. Burdick, L. Liu, and R.M. Strieter Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity J. Immunol. 167 2001 623 627
7. K.E. Cole, C.A. Strick, T.J. Paradis, K.T. Ogborne, M. Loetscher, R.P. Gladue, W. Lin, J.G. Boyd, B. Moser, D.E. Wood, B.G. Sahagan, and K. Neote Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3 J. Exp. Med. 187 1998 2009 2021
8. L. Corey, A.G. Langenberg, R. Ashley, R.E. Sekulovich, A.E. Izu, J.M. Douglas Jr., H.H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A.A. Adimora, P. Leone, C.L. Dekker, R.L. Burke, W.P. Leong, and S.E. Straus Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group JAMA 282 1999 331 340
9. D.T. Fleming, G.M. McQuillan, R.E. Johnson, A.J. Nahmias, S.O. Aral, F.K. Lee, and M.E. St. Louis Herpes simplex virus type 2 in the United States, 1976 to 1994 N. Engl. J. Med. 337 1997 1105 1111
10. W.S. Gallichan, R.N. Woolstencroft, T. Guarasci, M.J. McCluskie, H.L. Davis, and K.L. Rosenthal Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract J. Immunol. 166 2001 3451 3457
11. S.J. Gibson, J.M. Lindh, T.R. Riter, R.M. Gleason, L.M. Rogers, A.E. Fuller, J.L. Oesterich, K.B. Gorden, X. Qiu, S.W. McKane, R.J. Noelle, R.L. Miller, R.M. Kedl, P. Fitzgerald-Bocarsly, M.A. Tomai, and J.P. Vasilakos Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod Cell Immunol. 218 2002 74 86
12. M. Gierynska, U. Kumaraguru, S.K. Eo, S. Lee, A. Krieg, and B.T. Rouse Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes J. Virol. 76 2002 6568 6576
13. N. Gill, K.L. Rosenthal, and A.A. Ashkar NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection J. Virol. 79 2005 4470 4478
14. B. Halioua, and J.E. Malkin Epidemiology of genital herpes - recent advances Eur. J. Dermatol. 9 1999 177 184
15. A.M. Harandi, K. Eriksson, and J. Holmgren A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection J. Virol. 77 2003 953 962
16. C.J. Harrison, L. Jenski, T. Voychehovski, and D.I. Bernstein Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection Antiviral Res. 10 1988 209 223
17. C.J. Harrison, R.L. Miller, and D.I. Bernstein Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs Antimicrob. Agents Chemother. 38 1994 2059 2064
18. H. Hemmi, T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat. Immunol. 3 2002 196 200
19. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira A Toll-like receptor recognizes bacterial DNA Nature 408 2000 740 745
20. U.R. Hengge, B. Benninghoff, T. Ruzicka, and M. Goos Topical immunomodulators - progress towards treating inflammation, infection, and cancer Lancet Infect. Dis. 1 2001 189 198
21. D. Jarrossay, G. Napolitani, M. Colonna, F. Sallusto, and A. Lanzavecchia Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells Eur. J. Immunol. 31 2001 3388 3393
22. N. Kadowaki, S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, and Y.J. Liu Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens J. Exp. Med. 194 2001 863 869
23. C. Kaushic, A.A. Ashkar, L.A. Reid, and K.L. Rosenthal Progesterone increases susceptibility and decreases immune responses to genital herpes infection J. Virol. 77 2003 4558 4565
24. D.M. Koelle, and L. Corey Recent progress in herpes simplex virus immunobiology and vaccine research Clin. Microbiol. Rev. 16 2003 96 113
25. A.M. Krieg CpG motifs in bacterial DNA and their immune effects Annu. Rev. Immunol. 20 2002 709 760
26. A.M. Krieg Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides Curr. Oncol. Rep. 6 2004 88 95
27. A. Krug, A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R. Bals, T. Giese, H. Engelmann, S. Endres, A.M. Krieg, and G. Hartmann Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12 Eur. J. Immunol. 31 2001 3026 3037
28. F.N. Lauw, A.J. Simpson, J.M. Prins, S.J. van Deventer, W. Chaowagul, N.J. White, and P.T. van der The CXC chemokines gamma interferon (IFN-gamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis Infect. Immun. 68 2000 3888 3893
29. M.T. Liu, B.P. Chen, P. Oertel, M.J. Buchmeier, D. Armstrong, T.A. Hamilton, and T.E. Lane The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease J. Immunol. 165 2000 2327 2330
30. T. Liu, T. Matsuguchi, N. Tsuboi, T. Yajima, and Y. Yoshikai Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice Infect. Immun. 70 2002 6638 6645
31. A.D. Luster, and J.V. Ravetch Biochemical characterization of a gamma interferon-inducible cytokine (IP-10) J. Exp. Med. 166 1987 1084 1097
32. S. Mahalingam, J.M. Farber, and G. Karupiah The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo J. Virol. 73 1999 1479 1491
33. P.M. Murphy, M. Baggiolini, I.F. Charo, C.A. Hebert, R. Horuk, K. Matsushima, L.H. Miller, J.J. Oppenheim, and C.A. Power International union of pharmacology. XXII. Nomenclature for chemokine receptors Pharmacol. Rev. 52 2000 145 176
34. L. Naesens, and E. De Clercq Recent developments in herpesvirus therapy Herpes 8 2001 12 16
35. N. O'Farrell Increasing prevalence of genital herpes in developing countries: implications for heterosexual HIV transmission and STI control programmes Sex Transm. Infect. 75 1999 377 384
36. K. Ogasawara, S. Hida, Y. Weng, A. Saiura, K. Sato, H. Takayanagi, S. Sakaguchi, T. Yokochi, T. Kodama, M. Naitoh, J.A. De Martino, and T. Taniguchi Requirement of the IFN-alpha/beta-induced CXCR3 chemokine signalling for CD8+ T cell activation Genes Cells 7 2002 309 320
37. C. Pasare, and R. Medzhitov Toll-like receptors: linking innate and adaptive immunity Adv. Exp. Med. Biol. 560 2005 11 18
38. R.B. Pyles, D. Higgins, C. Chalk, A. Zalar, J. Eiden, C. Brown, G. Van Nest, and L.R. Stanberry Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection J. Virol. 76 2002 11387 11396
39. D. Sajic, A.A. Ashkar, A.J. Patrick, M.J. McCluskie, H.L. Davis, K.L. Levine, R. Holl, and K.L. Rosenthal Parameters of CpG oligodeoxynucleotide- induced protection against intravaginal HSV-2 challenge J. Med. Virol. 71 2003 561 568
40. T.P. Salazar-Mather, T.A. Hamilton, and C.A. Biron A chemokine-to- cytokine-to-chemokine cascade critical in antiviral defense J. Clin. Invest. 105 2000 985 993
41. T. Schacker The role of HSV in the transmission and progression of HIV Herpes 8 2001 46 49
42. T.W. Schacker, M. Conant, C. Thoming, T. Stanczak, Z. Wang, and M. Smith Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study Antimicrob. Agents Chemother. 46 2002 3243 3248
43. S.L. Spruance, S.K. Tyring, M.H. Smith, and T.C. Meng Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study J. Infect. Dis. 184 2001 196 200
44. L.R. Stanberry, S.L. Spruance, A.L. Cunningham, D.I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F.Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin Glycoprotein-d-adjuvant vaccine to prevent genital herpes N. Engl. J. Med. 347 2002 1652 1661
45. L. Van Damme, G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiegne-Traore, C. Uaheowitchai, S.S. Karim, B. Masse, J. Perriens, and M. Laga Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial Lancet 360 2002 971 977
46. J.P. Vasilakos, R.M. Smith, S.J. Gibson, J.M. Lindh, L.K. Pederson, M.J. Reiter, M.H. Smith, and M.A. Tomai Adjuvant activities of immune response modifier R-848: comparison with CpG ODN Cell Immunol. 204 2000 64 74
47. H. Wagner The immunobiology of the TLR9 subfamily Trends Immunol. 25 2004 381 386
48. R.D. Weeratna, S.R. Makinen, M.J. McCluskie, and H.L. Davis TLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848) Vaccine 23 2005 5263 5270
49. L. Zeitlin, and K.J. Whaley Microbicides for preventing transmission of genital herpes Herpes 9 2002 4 9